NASDAQ:UPB Upstream Bio (UPB) Stock Price, News & Analysis $11.17 -0.19 (-1.67%) Closing price 04:00 PM EasternExtended Trading$11.18 +0.02 (+0.13%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Upstream Bio Stock (NASDAQ:UPB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Upstream Bio alerts:Sign Up Key Stats Today's Range$10.74▼$11.4650-Day Range$6.40▼$11.6852-Week Range$5.14▼$29.46Volume264,020 shsAverage Volume332,771 shsMarket Capitalization$600.88 millionP/E RatioN/ADividend YieldN/APrice Target$56.50Consensus RatingBuy Company OverviewUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.Read More… Upstream Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreUPB MarketRank™: Upstream Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 739th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingUpstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUpstream Bio has received no research coverage in the past 90 days.Read more about Upstream Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.Read more about Upstream Bio's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for UPB. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUpstream Bio does not currently pay a dividend.Dividend GrowthUpstream Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for UPB. News and Social Media2.2 / 5News Sentiment0.93 News SentimentUpstream Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Upstream Bio this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Upstream Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Upstream Bio's insider trading history. Receive UPB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address UPB Stock News HeadlinesUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16 at 2:16 PM | tipranks.comUpstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher PotencyJune 16 at 12:53 AM | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.June 16, 2025 | Brownstone Research (Ad)Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI CongressJune 15 at 8:30 AM | quiverquant.comTranslational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ReceptorJune 15 at 7:45 AM | globenewswire.comUpstream Bio (NASDAQ:UPB) Upgraded at Wall Street ZenJune 9, 2025 | americanbankingnews.comUpstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025June 5, 2025 | globenewswire.comUpstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comSee More Headlines UPB Stock Analysis - Frequently Asked Questions How have UPB shares performed this year? Upstream Bio's stock was trading at $16.44 on January 1st, 2025. Since then, UPB stock has decreased by 32.1% and is now trading at $11.17. View the best growth stocks for 2025 here. How were Upstream Bio's earnings last quarter? Upstream Bio, Inc. (NASDAQ:UPB) announced its earnings results on Tuesday, May, 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.02. The company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. When did Upstream Bio IPO? Upstream Bio (UPB) raised $200 million in an initial public offering on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO. Who are Upstream Bio's major shareholders? Upstream Bio's top institutional shareholders include Wellington Management Group LLP (2.44%), Siren L.L.C. (1.47%), Siren L.L.C. (1.47%) and Nantahala Capital Management LLC (1.11%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc. View institutional ownership trends. How do I buy shares of Upstream Bio? Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2025Today6/16/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UPB Previous SymbolNASDAQ:UPB CIK2022626 Webupstreambio.com Phone(781) 208-2466FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Target$56.50 High Stock Price Target$75.00 Low Stock Price Target$38.00 Potential Upside/Downside+413.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.30 million Price / Sales257.61 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,794,000Free FloatN/AMarket Cap$591.47 million OptionableN/A BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:UPB) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.